Drug details

Novoseven (coagulation factor viia (recombinant))

type of Coagulation Factors

NovoSeven (coagulation factor Vlla recombinant) is a blood coagulant compound. NovoSeven is prescribed for the prevention and treatment of bleeding in hemophilia A or B, patients with inhibitors to Factor VIII or Factor IX, and acquired hemophilia.

This drug may have the following side effects:
  • headache,
  • dizziness,
  • fever,
  • nausea, or
  • injection site reactions (pain, redness, or irritation),
  • vomiting.
The following drugs are related to Novoseven, either as a replacement or used together:
  • Advate ([antihemophilic factor (recombinant), plasma/albumin-free method] for intravenous injection)
  • Adynovate (antihemophilic factor (recombinant), pegylated for injection)
  • Alprolix ([coagulation factor ix (recombinant), fc fusion protein], lyophilized powder for solution for intravenous injection)
  • Altuviiio (antihemophilic factor (recombinant), fc-vwf-xten fusion protein-ehtl)
  • Novoeight (antihemophilic factor (recombinant) lyophilized powder for intravenous injection)
  • Jivi (antihemophilic factor (recombinant), pegylated-aucl for injection)
  • Nuwiq (antihemophilic factor recombinant intravenous infusion)
  • Humate-P (antihemophilic factor/von willebrand factor complex (human) injection)
  • Bebulin VH (factor ix complex intravenous administration)
  • Coagadex (coagulation factor x lyophilized powder)
  • Idelvion (coagulation factor ix (recombinant) albumin fusion protein lyophilized powder intravenous injection)
  • Rixubis (coagulation factor ix (recombinant) for intramuscular injection)
  • Sevenfact (coagulation factor viia (recombinant)-jncw for injection)
  • Esperoct ([antihemophilic factor (recombinant), glycopegylated-exei] injection)
  • Profilnine (factor ix complex intravenous administration)
  • Octaplas (pooled plasma (human) solvent/detergent)